Does milrinone (phosphodiesterase 3 inhibitor) lower blood pressure in patients with intracranial vasospasm post subarachnoid hemorrhage (SAH) and what is the data on its usage in this context?

Milrinone in Post-SAH Vasospasm: Blood Pressure Effects, Clinical Data, and Mechanism

Does Milrinone Lower Blood Pressure?

Yes, milrinone can cause systemic hypotension as a significant side effect, though the magnitude varies—during intraarterial infusions blood pressure typically remains stable, but continuous intravenous administration frequently causes hypotension requiring aggressive vasopressor support. 1, 2

Hemodynamic Effects in Clinical Practice

• Intraarterial milrinone (2-8 mg bolus) causes only moderate increases in heart rate while systemic arterial pressure remains largely unchanged 2
• Intravenous milrinone (0.5 µg/kg/min continuous infusion) frequently causes hypotension—in one controlled study, 24% of patients required premature discontinuation due to inability to maintain mean arterial pressure ≥100 mmHg despite norepinephrine doses up to 1.5 µg/kg/min 3
• The FDA label explicitly warns: "blood pressure and heart rate should be monitored and the rate of infusion slowed or stopped in patients showing excessive decreases in blood pressure" 1

Critical Caveat on Blood Pressure Management

• This hypotensive effect creates a therapeutic paradox: milrinone is used to treat vasospasm/DCI, but the resulting hypotension can worsen cerebral perfusion 3
• Milrinone must be combined with aggressive induced hypertension (typically norepinephrine-based) to maintain MAP >90-100 mmHg 4, 3, 5
• The 2023 AHA/ASA guidelines note that hemodynamic augmentation with various agents including milrinone showed no difference in DCI when used prophylactically, suggesting reactive rather than prophylactic use 6

---

Clinical Data on Milrinone for Post-SAH Vasospasm

Milrinone shows promising efficacy for treating cerebral vasospasm after aneurysmal SAH, with the strongest evidence supporting its use as rescue therapy for refractory vasospasm, though it requires careful hemodynamic monitoring and frequently necessitates premature discontinuation due to hypotension. 3, 7

Evidence for Efficacy

• Angiographic reversal: Intraarterial milrinone produces 53±37% increase in arterial diameter of vasospastic vessels (p<0.0001) 2
• Clinical improvement: 76% of patients with refractory vasospasm showed significant neurological improvement within 24 hours of rescue therapy with intraarterial milrinone 7
• Functional outcomes: In a controlled before-after study, IV milrinone was independently associated with lower 6-month functional disability (adjusted OR 0.28,95% CI 0.10-0.77) and reduced vasospasm-related infarction (adjusted OR 0.19,95% CI 0.04-0.94) 3
• Reduced need for angioplasty: IV milrinone decreased endovascular angioplasty requirements from 53% to 15% (adjusted OR 0.12,95% CI 0.04-0.38) 3

Perfusion Improvements

• Quantifiable hemodynamic benefit: Milrinone plus norepinephrine-based therapy reduced median T4 volumes (tissue with >4 second time-to-peak delay) from 40 cc to 10 cc, and mean focal TTP delays from 2.5±2.1 seconds to 1.7±1.9 seconds 5
• Visible resolution of macroscopic vasospasm on CTA occurred in 43% of patients with verified vasospasm 5

Safety Profile and Tolerance Issues

• Premature discontinuation: 29% of patients required stopping IV milrinone due to poor tolerance, primarily inability to maintain adequate blood pressure despite high-dose vasopressors 3
• Metabolic complications: Milrinone causes significant polyuria (creatinine clearance 191 [153-238] ml/min) and increased incidence of hyponatremia and hypokalemia 3
• Cardiac effects: Arrhythmia and myocardial ischemia were infrequent, though the FDA label warns of potential for increased ventricular ectopy and shortened AV node conduction 1, 3
• Recurrence: 23% of patients experienced vasospasm recurrence within 48 hours after intraarterial milrinone, requiring repeat intervention 2

Guideline Context

• The 2023 AHA/ASA guidelines mention milrinone as one of several agents used for hemodynamic augmentation but note that prophylactic hemodynamic augmentation showed no difference in DCI compared to reactive approaches 6
• Current guidelines emphasize that induced hypertension may be reasonable for symptomatic DCI, with milrinone serving as an adjunct to maintain cardiac output while achieving blood pressure targets 6, 4

---

Mechanism of Action

Milrinone is a phosphodiesterase-3 (PDE-3) inhibitor that produces cerebral vasodilation through cyclic AMP-mediated smooth muscle relaxation while simultaneously providing positive inotropic support to maintain cardiac output during induced hypertension. 8, 2

Molecular Mechanism

• PDE-3 inhibition: Blocks breakdown of cyclic adenosine monophosphate (cAMP) in vascular smooth muscle and cardiac myocytes 8, 2
• Dual cardiovascular effects:
  • Vasodilation through increased cAMP in arterial smooth muscle
  • Positive inotropy through increased cAMP in cardiac myocytes 8, 2

Therapeutic Advantages in Vasospasm

• Direct cerebral vasodilation: Acts on spastic cerebral arteries to reverse vasospasm independent of systemic blood pressure effects 2, 5
• Cardiac output augmentation: The positive inotropic effect helps maintain cerebral perfusion pressure during induced hypertension protocols 6, 3, 5
• Anti-inflammatory properties: Milrinone has additional anti-inflammatory effects that may contribute to neuroprotection beyond simple vasodilation 8

Clinical Application of Mechanism

• Synergy with induced hypertension: The combination of milrinone's vasodilatory and inotropic effects theoretically optimizes cerebral perfusion—vasodilation reverses vasospasm while inotropy maintains the elevated blood pressure needed for adequate cerebral perfusion pressure 3, 5
• Offset of PEEP effects: In patients with concurrent ARDS requiring high PEEP (which decreases venous return and cerebral blood flow), milrinone's inotropic effects may help maintain cardiac output and cerebral perfusion 6

Practical Pitfall

• The mechanism creates a clinical challenge: while milrinone dilates cerebral vessels (beneficial), it also dilates systemic vessels (causing hypotension), requiring aggressive vasopressor support to maintain the induced hypertension necessary for adequate cerebral perfusion pressure 3, 5